Gastric or Gastroesophageal Junction: Study of Pembrolizumab (MK-3475) Plus Chemotherapy
Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal
Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
What is the safety, efficacy, and tolerability of the research study drug pembrolizumab
(MK-3475) in combination with cisplatin and capecitabine or cisplatin and 5-fluorouracil
(5-FU) or FLOT (docetaxel, oxaliplatin, 5-FU and leucovorin)?
Basic Study Information
Purpose:Location: Cancer Center
If you decide to participate in this research study, your study doctor will assign
you to one of three chemotherapy treatments: XP (cisplatin and capecitabine), FP (cisplatin
and 5-FU) or FLOT (docetaxel, oxaliplatin, 5-FU and leucovorin). Once you are assigned
a chemotherapy treatment, you will be assigned by chance to receive either chemotherapy
+ pembrolizumab before and after surgery followed by pembrolizumab only or chemotherapy
+ placebo (look-alike with no active ingredients) before and after surgery followed
by placebo only. You may still be able to continue in the study if you are unable
to have or no longer need surgery. The study doctor will discuss this with you.
You will be assigned by chance to get either pembrolizumab or placebo (a look alike
with no active ingredients). You have a 1 in 2 chance of getting placebo only. Neither
you nor the study doctor will know if you are receiving pembrolizumab or placebo.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03221426?term=KEYNOTE-585&rank=1
Study Reference #: IGIE17066
Lead Researcher (Principal Investigator)
Lead Researcher: Mohamedtaki Tejani, MD
Study Contact InformationStudy Coordinator: Chris Le Feber
Phone: (585) 275-0407
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search